Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 28:34:100739.
doi: 10.1016/j.lanepe.2023.100739. eCollection 2023 Nov.

Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study

Henrik Toft Sørensen  1   2 , Lars Pedersen  1 , Nick van Es  3   4 , Harry R Büller  3   4 , Erzsébet Horváth-Puhó  1
Affiliations

Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study

Henrik Toft Sørensen et al. Lancet Reg Health Eur. .

Abstract

Background: Despite recent improvements in the treatment of cancer, little is known about the long-term survival in patients with cancer and venous thromboembolism. We aimed to examine the five-year mortality of venous thromboembolism in cancer patients in a large population-based cohort study.

Methods: Using Danish healthcare registries from 1995 to 2020, we obtained data on cancer patients with venous thromboembolism and comparison cohorts of cancer patients without venous thromboembolism, matched in terms of cancer type, age, sex, and year of cancer diagnosis, and adjusted for level of comorbidity and frailty using the Charlson Comorbidity Index Score and Hospital Frailty Risk Score, marital status, use of selected medications, and recent surgery (<90 days).

Findings: During the study period, 886,536 patients were diagnosed with cancer. Of 1882 cancer patients diagnosed at the time of their venous thromboembolism, 44.4% (835/1882) had distant metastases. In this cohort, the one- and five-year mortality cumulative incidences were 68% (1284/1882) and 84% (1578/1882), respectively, in contrast to 38% (2135/5549) and 67% (3653/5549) in the comparison cohort. The mortality rate ratio was 4.34 (95% confidence interval [CI], 3.95-4.78) for the first year of follow-up and 3.44 (95% CI 3.17-3.73) for the five-year follow-up period. Of the 23,366 patients diagnosed with venous thromboembolism after cancer diagnosis, 18% (4183/23,366) had distant metastases at the time of cancer diagnosis. The cumulative incidence of death at one year was 45% (10,465/23,366; mortality rate ratio 3.48, 95% CI 3.37-3.60) and at five years 69% (15,669/23,366; mortality rate ratio 2.57, 95% CI 2.50-2.63).

Interpretation: Despite improved cancer treatment, venous thromboembolism in cancer patients is strongly associated with a poor prognosis.

Funding: The study was supported by grants from the Independent Research Fund Denmark (record no. 3101-00102B) and the Karen Elise Jensen Foundation.

Keywords: Cancer; Cohort study; Prognosis; Pulmonary embolism; Venous thrombosis.

PubMed Disclaimer

Conflict of interest statement

The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study.

Figures

Fig. 1
Fig. 1
Study flowchart illustrating thecohorts.
Fig. 2
Fig. 2
Survival curves for patients with venous thromboembolism concurrent with a cancer diagnosis and a matched comparison cancercohort.
Fig. 3
Fig. 3
Survival curves for patients with venous thromboembolism after a cancer diagnosis and a matched comparison cancercohort.
Fig. 4
Fig. 4
Survival curves for patients with venous thromboembolism concurrent with a cancer diagnosis and a matched comparison cancer cohort, by cancerstage.
Fig. 5
Fig. 5
Survival curves for patients with venous thromboembolism after a cancer diagnosis and a matched comparison cancer cohort, by cancerstage.
See this image and copyright information in PMC

References

    1. Bouillaud S., Bouillaud J. De l’obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med. 1823;1:188–204.
    1. Mulder F.I., Horvath-Puho E., van Es N., et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–1969. - PubMed
    1. Chee C.E., Ashrani A.A., Marks R.S., et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123(25):3972–3978. - PMC - PubMed
    1. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. - PubMed
    1. Weitz J.I., Haas S., Ageno W., et al. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 2020;50(2):267–277. - PubMed

LinkOut - more resources